Difference between revisions of "Melanoma, KIT-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 13: Line 13:
 
=Advanced or metastatic disease, TKI-naive=
 
=Advanced or metastatic disease, TKI-naive=
 
==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}==
 
==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}===
 
===Regimen variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 25: Line 25:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
−
 
 
*Gene: KIT
 
*Gene: KIT
 
*Alteration: amplification and mutation
 
*Alteration: amplification and mutation
 
*Acceptable methods of measurement: PCR or HPLC
 
*Acceptable methods of measurement: PCR or HPLC
−
 
+
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
−
 
 
*[[Imatinib (Gleevec)]] as follows:
 
*[[Imatinib (Gleevec)]] as follows:
 
**Starting dose: 400 mg PO once per day
 
**Starting dose: 400 mg PO once per day
 
**Upon progression: 400 mg PO twice per day
 
**Upon progression: 400 mg PO twice per day
−
 
 
'''Continued indefinitely'''
 
'''Continued indefinitely'''
−
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #2 {{#subobject:d1f61b|Variant=1}}===
 
===Regimen variant #2 {{#subobject:d1f61b|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 51: Line 51:
 
|}
 
|}
 
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
 
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
−
 
 
*Gene: KIT
 
*Gene: KIT
 
*Alteration: amplification or mutation
 
*Alteration: amplification or mutation
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
−
 
 
*[[Imatinib (Gleevec)]] 400 mg PO once or twice per day
 
*[[Imatinib (Gleevec)]] 400 mg PO once or twice per day
−
 
 
'''Continued indefinitely'''
 
'''Continued indefinitely'''
−
 
+
</div></div>
 
===References===
 
===References===
−
 
 
#'''MSKCC 07-014:''' Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. [https://doi.org/10.1001/jama.2011.746 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21642685 PubMed] NCT00470470
 
#'''MSKCC 07-014:''' Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. [https://doi.org/10.1001/jama.2011.746 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21642685 PubMed] NCT00470470
 
#'''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [https://doi.org/10.1200/jco.2012.47.7836 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23775962 PubMed] NCT00424515
 
#'''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [https://doi.org/10.1200/jco.2012.47.7836 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23775962 PubMed] NCT00424515
−
 
 
[[Category:Melanoma regimens]]
 
[[Category:Melanoma regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Skin cancers]]
 
[[Category:Skin cancers]]

Revision as of 12:17, 12 January 2023

Back to Top

Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.

1 regimens on this page
2 variants on this page


Advanced or metastatic disease, TKI-naive

Imatinib monotherapy

Regimen variant #1, pre-planned escalation

Study Years of enrollment Evidence
Hodi et al. 2013 (BUS255) 2006-2011 Phase 2

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification and mutation
  • Acceptable methods of measurement: PCR or HPLC

Targeted therapy

  • Imatinib (Gleevec) as follows:
    • Starting dose: 400 mg PO once per day
    • Upon progression: 400 mg PO twice per day

Continued indefinitely


Regimen variant #2

Study Years of enrollment Evidence
Carvajal et al. 2011 (MSKCC 07-014) 2007-2010 Phase 2

Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification or mutation

Targeted therapy

Continued indefinitely

References

  1. MSKCC 07-014: Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. link to original article contains dosing details in abstract link to PMC article PubMed NCT00470470
  2. BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00424515
Retrieved from "https://hemonc.org/w/index.php?title=Melanoma,_KIT-mutated&oldid=65528"